Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial

IMPORTANCE: Dapagliflozin has been shown to improve overall health status based on aggregate summary scores of the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction enrolled in the Dapagliflozin Evaluation to Improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Peikert, Alexander, Chandra, Alvin, Kosiborod, Mikhail N., Claggett, Brian L., Desai, Akshay S., Jhund, Pardeep S., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Hernandez, Adrian F., Shah, Sanjiv J., Janssens, Stefan P., Bělohlávek, Jan, Borleffs, C. Jan Willem, Dobreanu, Dan, Langkilde, Anna Maria, Bengtsson, Olof, Petersson, Magnus, McMurray, John J. V., Solomon, Scott D., Vaduganathan, Muthiah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200027/
https://www.ncbi.nlm.nih.gov/pubmed/37208998
http://dx.doi.org/10.1001/jamacardio.2023.1342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200027/
https://www.ncbi.nlm.nih.gov/pubmed/37208998
http://dx.doi.org/10.1001/jamacardio.2023.1342

Ejemplares similares